Mitali Desai•Director of Pharmacy Business Services, UMass Memorial Medical Center
Executive Summary
12 quotes
Concerns Raised
The IRA's price negotiation will eliminate the 340B savings spread for Medicare patients, causing a significant negative financial impact on hospitals.
The negative financial impact is projected to increase annually as more drugs are added to the negotiation list.
Ongoing manufacturer restrictions on contract pharmacies are already limiting access to 340B savings and complicate future financial planning.
The loss of 340B savings could strain hospitals' ability to provide uncompensated care and other community benefits.
Opportunities Identified
The IRA's 'maximum fair price' will become the new 'best price', lowering the 340B ceiling price and increasing savings for drugs dispensed to non-Medicare patients.
State laws in Arkansas and Louisiana are successfully pushing back against manufacturer restrictions, potentially creating a model for other states to follow.